

1 **The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monotherapy**
2 **and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis**

3 Albertus Ari Adrianto¹

4 Ignatius Riwanto¹

5 Udadi Sadhana²

6 Dewi Kartikawati Paramita^{3, 4, 5}

7 Henry Setyawan⁶

8 Kevin Christian Tjandra⁷

9 Danendra Rakha Putra Respati⁷

10 Derren David Christian Homenta Rampengan⁸

11 Roy Novri Ramadhan⁹

12 Gastin Gabriel Jangkang¹⁰

13 Endang Mahati¹¹

14 ¹Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang,
15 Indonesia

16 ²Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro,
17 Semarang, Indonesia

18 ³Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing,
19 Universitas Gadjah Mada, Yogyakarta, Indonesia

20 ⁴Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas
21 Gadjah Mada, Yogyakarta, Indonesia;

22 ⁵Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia

23 ⁶Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang,
24 Indonesia;

25 ⁷Department of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

26 ⁸Medical Program, Faculty of Medicine, Universitas Sam Ratulangi

27 ⁹Medical Program, Faculty of Medicine, Universitas Airlangga

28 ¹⁰Medical Program, Faculty of Medicine, Universitas Lambung Mangkurat

29 ¹¹Department of Pharmacology and Therapeutic, Faculty of Medicine, Diponegoro University,
30 Semarang, Indonesia

31 *Correspondence: Albertus Ari Adrianto

32 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
J. Prof. Sudarto, Tembalang, Kec. Tembalang, Kota Semarang, Jawa Tengah 50275

33 Tel +628122824838

34 Fax -

35 Email: medpubdiponegoro@gmail.com

36 ***Abstract***

37 ***Background:*** Colorectal cancer (CRC) ranks third globally in cancer-related mortality, with
38 rising incidence, particularly in Asia, projecting a 60% surge by 2030. Metastatic CRC
39 (mCRC) presents a significant challenge with a grim 5-year survival rate of 14%. Emerging
40 evidence suggests that tumors with DNA mismatch repair deficiency (dMMR) and high
41 microsatellite instability (MSI-H) respond well to immune checkpoint inhibitors (ICIs),
42 marking a paradigm shift in therapeutic approaches. This systematic review and meta-
43 analysis aim to comprehensively assess Pembrolizumab, Nivolumab, and the combination of
44 Nivolumab and Ipilimumab in advanced CRC, considering their significant antitumor
45 efficacy in MSI-H/dMMR mCRC.

46 ***Methods:*** Following PRISMA guidelines and Cochrane Handbook standards, this study
47 covers 2014 to 2024, involving advanced CRC patients treated with ICIs. A comprehensive
48 literature search employed 12 independent authors across eight databases. Parameters such
49 as overall survival, progression-free survival, and objective response rate were extracted.
50 The Cochrane Collaboration's Risk of Bias version 2 tool assessed risk. Statistical analysis
51 utilized mean difference and risk ratios with random-effect models due to anticipated
52 heterogeneity. Robustness was ensured through publication bias analysis and sensitivity
53 meta-analysis. Linear regression explored associations in subgroup analysis.

54 ***Results:*** The meta-analysis evaluated ORR and OS across different immunotherapy
55 interventions. Nivolumab, Nivolumab+Ipilimumab, and Pembrolizumab exhibited varying
56 ORR and OS effect sizes with corresponding heterogeneity levels. Progression-free survival

57 *(PFS) analysis also showed diverse effect sizes and heterogeneity levels across the three*
58 *interventions. The study provides a comprehensive overview of response rates and survival*
59 *outcomes for these immunotherapies in advanced CRC.*

60 **Conclusions:** *The study concludes that combination immunotherapy, particularly Nivolumab*
61 *and Ipilimumab, presents a promising avenue for advanced CRC treatment, showing superior*
62 *efficacy. Pembrolizumab monotherapy also exhibited promise. While the study offers*
63 *valuable insights, the identified heterogeneity emphasizes the need for additional research.*
64 *Adverse effects were generally low, supporting the viability of the studied immunotherapies.*
65 *The study acknowledges limitations and calls for ongoing investigation to refine and validate*
66 *these findings, marking a pioneering effort in systematically comparing short-term and long-*
67 *term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC.*

68 **Keywords:** Colorectal Cancer Immunotherapy, PD-1 and CTLA-4 Combination, Nivolumab,
69 Ipilimumab, Pembrolizumab Efficacy and Safety Profiles

70 **Introduction**

71 Colorectal cancer (CRC) ranks as the third most common cause of cancer-related mortality
72 globally[1]. Over the past thirty years, the incidence of CRC has surged in many nations,
73 particularly in Asia, where a notable rise has been observed[2]. Projections indicate a
74 significant rise in its worldwide incidence, with an expected increase of 60% by the year 2030
75 [1,3]. The prognosis remains poor for individuals diagnosed with metastatic colorectal cancer
76 (mCRC), as evidenced by a 5-year survival rate of only 14%[4]. The incidence of CRC and its
77 associated mortality rate rise with advancing age, with a median age of diagnosis typically
78 reported as 68 years old. A striking 93% of CRC-related deaths are observed in individuals

79 aged 50 years and older. The relative survival rates at 5 and 10 years post-diagnosis for CRC
80 stand at 65% and 58%, respectively[5].

81

82 Until recently, the treatment choices available for individuals with inoperable colorectal cancer
83 worldwide have been predominantly confined to chemotherapy and targeted therapies[6].
84 Findings from several clinical trials indicate that CRC tumors identified by DNA mismatch
85 repair deficiency (dMMR) and a high level of microsatellite instability (MSI-H) exhibit
86 susceptibility to treatment with immune checkpoint inhibitors (ICIs)[7–9]. Tumors
87 characterized as MSI-H/dMMR possess an elevated tumor mutational burden, leading to the
88 generation of neoantigens, thereby rendering MSI-H/dMMR tumors more immunogenic
89 compared to those with proficient DNA mismatch repair mechanisms. Consequently, MSI-
90 H/dMMR tumors tend to harbor increased numbers of tumor-infiltrating lymphocytes, whose
91 function can be potentiated by ICI therapy. Patients with MSI-H/dMMR mCRC typically
92 derive less benefit from standard chemotherapy compared to those with microsatellite
93 stable/mismatch repair-proficient mCRC[10,11]. However, MSI-H/dMMR status serves as a
94 predictive indicator of favorable response to anti-programmed death (PD)-1 checkpoint
95 inhibitor therapy [8,12,13]

96

97 The interaction involving the PD-1 receptor and its ligands, PD-L1 and PD-L2, typically serves
98 as an immune checkpoint mechanism responsible for regulating the equilibrium between T-
99 cell activation, immune tolerance, and preventing immune-related tissue damage. This pathway
100 is often exploited by tumors to evade immune surveillance[14]. PD-1 is present on T, B, and
101 natural killer T cells, as well as activated monocytes and a significant portion of tumor-
102 infiltrating lymphocytes (TILs) in various malignancies[14]. When PD-L1 (found on cells of
103 diverse lineages) or PD-L2 (present on macrophages and dendritic cells) binds to the PD-1

104 receptor, it ultimately leads to the inhibition of T-cell function. Both PD-1 ligands have the
105 potential to be expressed either constitutively or induced in various cell types, which also
106 includes tumor cells[14]. Pembrolizumab is a selective humanized monoclonal antibody of the
107 immunoglobulin G4/ κ type, designed to specifically hinder the interaction between PD-1 and
108 PD-L1/PD-L2 by directly binding to PD-1[15]. Previous studies have shown that checkpoint
109 inhibitors targeting PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
110 including nivolumab and ipilimumab, respectively, synergize and stimulate an immune
111 response against tumors through separate but complementary mechanisms. Nivolumab, a
112 human monoclonal antibody blocking PD-1, has received accelerated approval from the U.S.
113 Food and Drug Administration (FDA) for use either alone or in combination with low-dose
114 ipilimumab in patients diagnosed with MSI-H or dMMR mCRC. Another findings also
115 reported that both pembrolizumab and nivolumab, inhibitors targeting PD-1, have
116 demonstrated significant antitumor efficacy in patients with previously treated MSI-H/dMMR
117 metastatic CRC[7–9].

118
119 Due to their distinct mechanism of action, immune checkpoint inhibitors are linked to adverse
120 events (AEs) that contrast with those typically associated with chemotherapy. These immune-
121 related AEs commonly impact various bodily systems including the skin, gastrointestinal (GI)
122 tract, lungs, kidneys, endocrine glands, and liver. Timely detection and appropriate
123 management of these AEs, which may involve the use of systemic corticosteroids as necessary,
124 could enhance outcomes for patients undergoing checkpoint inhibitor therapy (Brahmer et al.,
125 2018). Understanding the predictors of response and resistance to immunotherapy is crucial for
126 identifying patients who are most likely to benefit from these agents. Pembrolizumab,
127 Nivolumab, and Ipilimumab represent novel therapeutic options for patients with advanced
128 colorectal cancer, offering the potential for durable responses and improved survival outcomes.
129 Therefore, this systematic review and meta-analysis aims to provide a comprehensive overview

130 of the efficacy and safety profiles of Pembrolizumab, Nivolumab, and Ipilimumab in advanced
131 colorectal cancer, with insights into future directions and challenges in the immunotherapy
132 landscape.

133

134 **Material and Method**

135 Registration

136 The systematic review and meta-analysis titled "The Efficacy and Safety of Pembrolizumab,
137 Ipilimumab, and Nivolumab Monotherapy and Combination for Advanced Colorectal Cancer:
138 A Systematic Review and Meta-Analysis" was officially registered on the Prospero on 24
139 February 2024 with registration number: CRD42024512511

140

141 Eligibility criteria

142 This review adhered to the guidelines stipulated by the Preferred Reporting Items for
143 Systematic Reviews and Meta-Analyses (PRISMA) statement and the Cochrane
144 Handbook[16,17]. The inclusion criteria encompassed studies involving patients of any age
145 diagnosed with advanced or metastatic colorectal cancer, regardless of microsatellite
146 instability-high and/or mismatch repair-deficient (MSI-H/ dMMR) status, treated by
147 Pembrolizumab, Ipilimumab, and Nivolumab as the monotherapy or combination therapy. The
148 primary focus was assessing the efficacy and safety of this treatment. The criteria for inclusion
149 necessitated the availability of data on the mentioned primary outcomes published from 2014
150 until 2024. Furthermore, the eligible studies were restricted to observational designs
151 (cohort/case-control) or randomized clinical trials (RCTs) or clinical trial.

152

153 The exclusion criteria were technical reports, editor responses, narrative reviews, systematic
154 reviews, meta-analyses, non-comparative research, in silico studies, in vitro studies, in vivo
155 studies, scientific posters, study protocols, and conference abstracts. For data synthesis, the
156 study will be grouped based on relevant comparators that include the use of
157 Nivolumab+Ipilimumab, Nivolumab, and Pembrolizumab monotherapy.

158

159 Literature Search and Study Selection

160 A comprehensive search of English literature across eight international databases— Scopus,
161 PubMed, Cochrane Library, Sage pub, ProQuest, Science Direct, Research Gate,
162 Epistemonikos—was conducted by a team of 12 independent authors from inception until
163 February 1st, 2024. To capture all potentially relevant literature, a combination of keywords
164 was utilized, employed the following keywords: "Pembrolizumab" or "Nivolumab" or
165 "Ipilimumab" and "colorectal carcinoma" and "therapeutic". The studies were organized and
166 managed using the Mendeley Group Reference Manager in the authors' library. Initially,
167 duplicate articles were removed, followed by screening based on titles and abstracts. Each
168 researchers independently reviewed the titles and abstracts, resolving any disparities through
169 discussion until reaching an agreement. Subsequently, they collaborated in 6 pairs of group to
170 review the titles and abstracts of all retrieved articles. If necessary, the corresponding author
171 was involved to make the final decision. Articles that passed this initial screening underwent
172 full-text evaluation against predetermined inclusion/exclusion criteria. The full-text screening
173 was conducted by the same 12 independent researchers with any discrepancies resolved
174 through discussion with the corresponding author as the final decision maker.

175 **Table 1.** Keyword Used in Literature Searching

Database	Keywords
Scopus	"Pembrolizumab" or "Nivolumab" or "Ipilimumab" and "colorectal carcinoma" and "therapeutic"
PubMed	
Cochrane Library	
Sage pub	
ProQuest	
Science Direct	
Research Gate	
Epistemonikos	

176

177 Data Extraction

178 The following data were extracted for analytical purposes: study ID, publication year, country,
179 study design, sample size, baseline characteristics of participants (mean age and sex
180 distribution), follow-up duration, the number of participants in the buried and exposed K-wire
181 groups, and the outcomes of interest. These data, extracted by 12 independent authors, were
182 tabulated using Microsoft Excel 2019. The primary outcome assessment of efficacy
183 incorporated into two general parameters, survival and therapy response. The survival
184 parameter is indicated as overall survival (OS), progression-free survival (PFS) (The duration
185 spanning both the treatment period and the subsequent phase following the intervention for a
186 medical condition, such as cancer, wherein a patient sustains a state in which the disease neither
187 progresses nor deteriorates). Furthermore, the response evaluation was assessed by objective

188 response rate (ORR) These parameters were chosen to holistically evaluate the influence of the
189 therapeutic intervention among individuals afflicted with colorectal cancer. The adverse effect
190 occurred during the treatment indicated as our secondary outcomes.

191

192 *Risk of Bias Assessment*

193 The evaluation of bias risk was carried out by five independent authors utilizing validated
194 instruments. To assess the quality of the included Randomized Controlled Trials (RCTs), the
195 Cochrane Collaboration's Risk of Bias version 2 (RoB v2) tool was employed, comprising
196 methodological assessments across five domains: (a) randomization process; (b) deviations
197 from intended interventions; (c) missing outcome data; (d) measurement of the outcome; and
198 (e) selection of the reported results. The outcomes are depicted in Fig 2. The authors' appraisals
199 were categorized as "low risk," "high risk," or "some concerns" of bias. Two review authors
200 (KCT, DR) independently utilized the tool for each included study and documented supporting
201 information for their assessments of risk of bias in each domain. In evaluating the quality of
202 included cohort/case-control studies or non randomized clinical trial, the Risk Of Bias In Non-
203 randomised Studies - of Interventions (ROBINS-I) was utilized, covering seven domains: (1)
204 confounding; (2) selection of participants; (3) classification of intervention; (4) deviation from
205 intended intervention; (5) missing data; (6) measurement of outcomes; (7) selection of the
206 reported result. The authors' appraisals were categorized as "low risk," "high risk," or "some
207 concerns" of bias. Two review authors (KCT, DR) independently utilized the tool for each
208 included study and documented supporting information for their assessments of risk of bias in
209 each domain. Any disparities in risk of bias assessments or justifications were addressed
210 through discussion to achieve consensus between the two review authors (KCT, DR) If needed,
211 corresponding author (EM) served as an arbiter to facilitate resolution

212

213 *Statistical Analysis*

214 For the analytical synthesis of continuous variable outcomes, we employed the mean difference
215 (SMD) with 95% confidence intervals (95% CI), utilizing the Inverse-Variance formula.
216 Dichotomous variable outcomes were pooled into risk ratios (RR) with 95% CI using the
217 Mantel-Haenszel formula. Given the anticipated substantial heterogeneity due to variations in
218 population characteristics and follow-up durations, random-effect models were selected for this
219 review. Heterogeneity between studies was assessed using the I-squared (I²) statistic, where
220 values exceeding 50% were categorized as significant heterogeneity. To facilitate pooled
221 analysis, we employed a combined formula from Luo D et al.[15] and Wan X et al.[16] for
222 transforming data expressed as the median and interquartile range (IQR), or median, minimum,
223 and maximum into mean and standard deviations (SD).

224 *Reporting bias and Certainty assessment*

225 Publication bias analysis was conducted when there were more than 10 studies for each
226 outcome of interest. In cases of funnel plot asymmetry, a thorough examination of
227 characteristics aimed to discern whether observed asymmetry could be attributed to publication
228 bias or other factors like methodological heterogeneity among studies. All statistical analyses
229 were executed using JAMOVI 2.3. The robustness of outcomes was scrutinized through
230 sensitivity meta-analysis, exclusively considering studies with an overall low risk of bias.

231

232 In the subgroup analysis, a commonly employed statistical methodology for data analysis
233 involves elucidating associations between a dependent variable and one or more independent
234 variables. Utilizing linear regression, the model centers on the dependent variable (e.g., sample
235 size, age, sex, and follow-up duration), evaluating whether these variables influence the
236 observed associations. The selection of variables is guided by theoretical considerations and

237 their relevance to analytical objectives. JAMOVI 2.3 was employed for conducting subgroup
238 analysis, ensuring robust data interpretation.

239 **Result**

240 *Study Selection and Characteristics*

241 A comprehensive literature search across eight international databases identified a total of
242 27,974 studies. Then the filter of released date and type of article were performed, 15,955
243 articles were automatically removed before being included into screening process. After the
244 elimination of duplicate entries and initial screening based on titles and abstracts, 11,519
245 studies were removed due to irrelevant topics and 458 studies were removed due to non-RCT
246 and non-clinical trial studies, resulting in a final selection of 42 studies. Subsequently, a
247 thorough evaluation of these 42 studies in full-text format revealed that 24 studies did not meet
248 the desired outcomes and 5 studies were not retrievable. Consequently, only 13 studies satisfied
249 the eligibility criteria and were included in the final analysis, as illustrated in Figure 1. Sample
250 sizes ranged from 11 to 307, with follow-up durations varying from 5.3 month to 44.5 month.
251 A comprehensive overview of the baseline characteristics of the included studies is presented
252 in Table 2.

253

254

255

256 **Table 2.** Study Characteristic

No.	Title	Author ;Year	Country /Place	Study Design	Population									
					Sample size (n)	Male (n)	Female (n)	Age (years)	Intervention	Control	Intervention (n)	Control (n)	Follow-up	Dosage
1	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer[18]	Morse, et al; 2019	USA	Cohort	119	Nr	Nr	Nr	Nivolumab + Ipilimumab	Nil	119	Nil	13.4 months	Nivolumab 3 mg/kg plus 1 mg/kg ipilimumab Q3W followed by nivolumab 3 mg/kg Q2W
2	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in	O'Neil, et al; 2017	Canada, France, Italy, the Republic of Korea, Spain, the	Cohort	23	13	10	57 (40–78)	Pembrolizumab	Nil	23	Nil	5.3 months	10 mg/kg

	patients with advanced colorectal carcinoma[19]		United Kingdom, and the United States											
3	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal[20]	Ott, et al; 2017	Europe and the USA	Cohort	25	2	23	63 (46–82)	Pembrolizumab	Nil	25	Nil	10.6 months	10 mg/kg
4	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with	Cohen, et al; 2020	Nr	Non-randomized Clinical Trial	57	30	27	56.5 (45.8–63.8)	Nivolumab + Ipilimumab	Nil	57	Nil	18.1 months	3 mg/kg intravenously and ipilimumab 1 mg/kg intravenously

	microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study[21]													
5	Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)[22]	Okuma, et al; 2023	Japan	Non-randomized Clinical Trial	11	3	8	70 (54–78)	Nivolumab	Nil	11		24.7 months	240 mg/kg
6	Pembrolizumab versus chemotherapy	Diaz, et al; 2022	Japan	Randomized	307	153	154	62.5 (24–93)	Pembrolizumab	chemot	153	154	44.5 months	200 mg/kg

	py for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[23]			Clinical Trial						herapy				
7	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer[24]	André, et al; 2020	USA	Randomized Clinical Trial	307	153	154	63.0 (24–93)	Pembrolizumab	chemotherapy	153	154	32.4 months	200 mg/kg
8	Pembrolizumab in Asian patients with	Yoshino, et al; 2022	Japan, Korea, Singapore, and Taiwan	Randomized Clinical Trial	48	23	25	64 (24–83)	Pembrolizumab	chemotherapy	22	26	45.3 (range 38.1–57.8) months	200 mg/kg

	microsatellite-instability-high/mismatch-repair-deficient colorectal cancer[24]			al Trial										
9	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[7]	Le, et al; 2015	Nr	Cohort	41	24	17	46 (24–65)	Pembrolizumab	Nil	41	Nil	36 weeks	10 mg/kg
10	Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-	Overman, et al; 2017	8 countries	Non-randomized Clinical Trial	74	44	30	52.5 (44.0–64.0)	Nivolumab	Nil	74	Nil	12.0 months	3 mg/kg

	label, multicentre, phase 2 study[8]													
11	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study[25]	Morris, et al; 2017	USA	Non-randomized Clinical Trial	37	10	27	56 (51–64)	Nivolumab	Nil	37	Nil	10.1 months	3 mg/kg
12	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient	Lenz, et al; 2021	6 countries	Cohort	45	23	22	66 (21–85)	Nivolumab + Ipilimumab	Nil	45	Nil	24.2 months	Nivolumab 3 mg/kg and low-dose ipilimumab 1 mg/kg

	Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study[26]													
13	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer[27]	Overman, et al; 2018	USA	Cohort	119	70	49	58 (21-88)	Nivolumab + Ipilimumab	Nil	119	Nil	13.4 months	Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg

258 **Figure 1.** PRISMA 2020 flow diagram.

259 *Risk of Bias in Studies*

260 Each clinical trial and randomized controlled trial underwent a rigorous evaluation employing
261 the ROB-2 method. Among the identified studies, three exhibited a level of bias concern,
262 primarily attributed to confounding, classification of interventions, missing data, and reported
263 results. The visualization of the risk-of-bias assessment is presented in Figure 2.

264 **Figure 2.** (A) ROBINS-I Risk of Bias Assessment; (B) ROB-2 Risk of Bias Assessment

265 *Objective response rate (ORR)*

266 Three studies that administered Nivolumab reported ORR with an effect size of **0.34 [95% CI**
267 **0.18; -0.49, P<0.001]**. Heterogeneity was found to be moderate and the funnel plot shows no
268 evidence of heterogeneity.

269 **Figure 3.** (A) Forest plot of ORR nivolumab intervention; (B) Funnel plot of ORR nivolumab
270 intervention

271 Four studies that administered Nivolumab and Ipilimumab reported ORR with an effect size of
272 **0.53 [95% CI 0.42; -0.65, P<0.001]**. Heterogeneity was found to be high and the funnel plot
273 shows evidence true of heterogeneity.

274 **Figure 4.** (A) Forest plot of ORR Nivolumab and Ipilimumab intervention; (B) Funnel plot of
275 ORR Nivolumab and Ipilimumab intervention

276

277 Six studies that administered Pembrolizumab reported ORR with an effect size of **0.34 [95%**
278 **CI 0.19; 0.48, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows
279 evidence true of heterogeneity.

280 **Figure 5.** (A) Forest plot of ORR Pembrolizumab intervention; (B) Funnel plot of ORR
281 Pembrolizumab intervention

282

283 *Overall Survival*

284 Three studies that administered Nivolumab reported OS with an effect size of **0.68 [95% CI**
285 **0.52; 0.84, P<0.001]**. Heterogeneity was found to be moderate and the funnel plot shows no
286 evidence true of heterogeneity.

287 **Figure 6.** (A) Forest plot of OS Nivolumab intervention; (B) Funnel plot of OS Nivolumab
288 intervention

289 Four studies that administered Nivolumab and Ipilimumab reported OS with an effect size of
290 **0.84 [95% CI 0.81; 0.88, P<0.001]**. Heterogeneity was found to be absent and the funnel
291 plot shows no evidence true of heterogeneity.

292

293 **Figure 7.** (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of
294 OS nivolumab and Ipilimumab intervention

295 Five studies that administered Pembrolizumab reported OS with an effect size of **0.56 [95%**
296 **CI 0.37; 0.75, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows
297 evidence true of heterogeneity.

298

299 **Figure 8.** (A) Forest plot of OS Pembrolizumab intervention; (B) Funnel plot of OS
300 Pembrolizumab intervention

301

302 *Progression-free survival (PFS)*

303 Three studies that administered Nivolumab reported PFS with an effect size of **0.53 [95% CI**
304 **0.43; 0.64, P<0.001]**. Heterogeneity was found to be low and the funnel plot shows no evidence
305 true of heterogeneity

306

307 **Figure 9.** (A) Forest plot of PFS Nivolumab intervention; (B) Funnel plot of PFS Nivolumab
308 intervention

309 Four studies that administered Nivolumab and Ipilimumab reported PFS with an effect size of
310 **0.72 [95% CI 0.67; 0.77, P<0.001]**. Heterogeneity was found to be absent and the funnel
311 plot shows no evidence true of heterogeneity.

312

313 **Figure 10.** (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of
314 OS Nivolumab and Ipilimumab intervention

315

316 Five studies that administered Pembrolizumab reported PFS with an effect size of **0.53 [95%**
317 **CI 0.34; 0.72, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows
318 evidence true of heterogeneity.

319

320 **Figure 11.** (A) Forest plot of PFS Pembrolizumab intervention; (B) Funnel plot of PFS
321 Pembrolizumab intervention

322 The effect size of each subgroup is summarized in Table 3 below.

323 **Table 3.** Size effects comparison of each subgroup

324 **Objective Response Rate (ORR)**

Intervention	Effect Size (95% CI)
Nivolumab	0.34 (0.18; -0.49)
Nivolumab + Ipilimumab	0.53 (0.42; -0.65)
Pembrolizumab	0.34 (0.19; 0.48)

325 **Overall Survival (OS)**

Intervention	Effect Size (95% CI)
Nivolumab	0.68 (0.52; 0.84)
Nivolumab + Ipilimumab	0.84 (0.81; 0.88)
Pembrolizumab	0.56 (0.37; 0.75)

326 **Progression-Free Survival (PFS)**

Intervention	Effect Size (95% CI)
Nivolumab	0.53 (0.43; 0.64)
Nivolumab + Ipilimumab	0.72 (0.67; 0.77)
Pembrolizumab	0.53 (0.34; 0.72)

327 **Discussion**

328 Immunotherapy stands as a pivotal cornerstone in tumor control, and the exploration of
329 combination immunotherapy involving multiple agents has emerged as a promising strategy.
330 This comprehensive approach strategically intervenes in diverse immune response processes,
331 encompassing chemoradiotherapy, targeted therapy, and interactions with immune pathways.
332 By orchestrating a multifaceted anti-tumor immune response, combination immunotherapy
333 seeks to mitigate the risk of drug resistance, marking it as a highly promising avenue for
334 investigation[28].

335 Among the various combinations being studied, the concurrent administration of anti-PD-1
336 (nivolumab and ipilimumab) and anti-CTLA-4 (ipilimumab) has exhibited notable efficacy in
337 tumor treatment[29,30]. This combination has demonstrated positive outcomes and substantial
338 improvements in patients with metastatic melanoma, advanced renal cell carcinoma (RCC),
339 and metastatic colorectal cancer (CRC)[30]. Cope et al. reported superior response rates in
340 recurrent small cell lung cancer (SCLC) when treated with nivolumab plus ipilimumab,
341 surpassing conventional chemotherapy and suggesting potential long-term survival

342 benefits[31]. Additionally, Ready et al. provided evidence supporting the effectiveness and
343 tolerability of the combination of nivolumab and low-dose ipilimumab as a first-line treatment
344 for advanced/metastatic non-small cell lung cancer (NSCLC)[32].

345 In the realm of combination immunotherapy, the inclusion of pembrolizumab has further
346 broadened the horizon of treatment modalities. Pembrolizumab, an anti-PD-1 agent, has
347 demonstrated its efficacy in various malignancies[33,34]. The concurrent use of
348 pembrolizumab with nivolumab and ipilimumab has shown promising outcomes, particularly
349 in advanced RCC. Shao's conditional survival analysis of first-line treatment highlighted that
350 patients with advanced RCC undergoing pembrolizumab in combination with nivolumab and
351 ipilimumab therapy exhibited a high survival rate compared to those receiving sunitinib[35].
352 This accumulating evidence underscores the potential synergistic effects of combining
353 immunotherapeutic agents, notably anti-PD-1 and anti-CTLA-4, in conjunction with
354 pembrolizumab, opening new avenues for the advancement of cancer treatment modalities.

355

356 The primary objective of this investigation was to assess the effectiveness and safety of
357 immunotherapy drugs in the context of colorectal cancer. A comprehensive analysis was
358 conducted, incorporating data from a total of 13 studies, encompassing a sample size of 1337
359 patients. The assessment of Efficacy (ORR, OS, PFS) for each groups with the investigation of
360 adverse events and survival can validate the safety of this immunotherapy. However, AEs will
361 only be covered descriptively in this study due to the different ways in which they have been
362 presented in previous studies.

363

364 The combination of nivolumab and ipilimumab demonstrates the highest efficacy, with an
365 ORR of 0.53, OS of 0.84, and PFS of 0.72. Pembrolizumab monotherapy also shows promising
366 results, with an ORR of 0.34, OS of 0.56, and PFS of 0.53. However, the heterogeneity
367 observed in some of the outcomes highlights the need for further studies to confirm these
368 findings.

369 The combination of nivolumab and ipilimumab has been shown to be effective in various
370 cancers, including colorectal carcinoma. The combination of these two medicine may enhance
371 the immune response against cancer cells by targeting different checkpoints in the immune
372 system. The high efficacy observed in our meta-analysis supports the use of this combination
373 in mCRC patients[18].

374 Pembrolizumab, a PD-1 inhibitor, has been approved for the treatment of mCRC patients with
375 dMMR or MSI-H tumors. The promising results observed in our meta-analysis suggest that
376 pembrolizumab may be a viable treatment option for a broader range of mCRC patients. Further
377 research is needed to confirm these findings and to explore the optimal treatment strategies for
378 mCRC patients[19].

379 Ipilimumab+Nivolumab and Nivolumab monotherapy have been evaluated in earlier meta-
380 analyses conducted across multiple publications with varying cancer types. It has been reported
381 that the combination outperforms nivolumab monotherapy in terms of ORR and DCR, however
382 patients may experience increased AEs[36]. One particular instance where using
383 Ipilimumab+Nivolumab has been clearly demonstrated in multiple meta-analyses to result in
384 improved ORR response[37–39]. Ipilimumab+Nivolumab use, however, still requires cautious
385 consideration because of the possibility of excessive adverse effects. Therefore, more thorough
386 research is required to determine how each type of cancer is affected by the combination of
387 Ipilimumab and Nivolumab[40].

388 The Adverse Effects (AEs) found according to previous meta-analyses indicating a high
389 incidence of AEs in the gastrointestinal system. However, in contrast, with the endocrine
390 system, the use of anti-CTLA-4 or anti-PD-1 immunotherapy is reported to have a greater
391 potential to cause endocrine issues (such as hypothyroidism, hyperthyroidism, thyroiditis, and
392 adrenal insufficiency) in other cancers[41,42]. These findings are also in line with the study
393 conducted by Almutairi AR, et al., 2020, who stated that Healthcare providers must remain
394 vigilant in monitoring for immune-related adverse events (irAEs) subsequent to combined
395 therapeutic interventions[43].

396 Additionally, particular attention should be directed towards gastrointestinal and cutaneous
397 irAEs in the context of ipilimumab therapy. Furthermore, clinicians should be cognizant of the
398 potential occurrence of irAEs associated with hyperglycemia, thyroid dysfunction, hepatic
399 abnormalities, and musculoskeletal disorders following administration of nivolumab and
400 pembrolizumab[43]. However, this treatment strategy is still preferable compared to
401 conventional chemotherapy since it has better efficacy with the same adverse effects as stated
402 by O'bryne K, et al., 2023, There was no statistically significant difference in the occurrence
403 of adverse events (AEs) necessitating discontinuation between the combination of nivolumab
404 and ipilimumab (NIVO + IPI) and pembrolizumab combined with chemotherapy, as well as
405 between NIVO + IPI and pembrolizumab monotherapy. However, it is noteworthy that the
406 incidence of treatment-related grade ≥ 3 AEs was higher with NIVO + IPI compared to
407 pembrolizumab monotherapy[39].

408 *Strength and limitation*

409 To our knowledge, this study represents the first systematic review and meta-analysis that
410 compares both short-term and long-term effects of presently available anti-CTLA-4 and anti-
411 PD-1 combination or monotherapies for treating patients with CRC. The PICOS criteria

412 necessitated significant follow-up period in each trial to mitigate potential bias arising from
413 heavily censored data in the tails of treatment arms during the observation period.
414 Methodologically, the analysis was executed utilizing the meta library package in the Jamovi
415 for the comprehensive analysis. The metabias package facilitated the execution of the Egger
416 test, revealing evidence of heterogeneity for ORR, OS, and PFS outcomes. Additionally, the
417 funnel plots also indicated evidence of heterogeneity for these outcomes. However, it is
418 noteworthy that the prevalence of AEs, in general, remained at a low level, with instances of
419 either absent or non-significant heterogeneity for certain AEs.

420 However, this study does have some limitations. Due to variations in the presentation of
421 adverse events (AEs) across studies, with one individual potentially experiencing two or more
422 AEs simultaneously, extracting data posed challenges for us. Additionally, It can be quite
423 challenging to classify an AE as a potential immune-related AE (irAE), as this determination
424 may vary among trials or observers. This variability could introduce detection bias, particularly
425 because our analysis included both open-label and double-blind trials. Such variations might
426 result in an overestimation of the incidence of potential irAEs. Nevertheless, we made efforts
427 to mitigate this by only including patients treated with either anti-CTLA-4 or anti-PD-1
428 monotherapies or combination therapies, thereby excluding AEs that could be attributed to
429 other treatments or immunotherapies. Furthermore, we employed the random-effects model for
430 the meta-analyses and conducted subgroup analyses to address high heterogeneity, aiming to
431 accommodate potential variations in the outcomes observed across the included studies.
432 Moreover, significant statistical heterogeneity observed in most analyses is a crucial
433 consideration. Variations in study designs, tumor stage, prior treatment history, and other
434 characteristic among the included studies could have contributed to this heterogeneity.

435 **Conclusion**

436 In conclusion, the exploration of combination immunotherapy involving anti-PD-1 and anti-
437 CTLA-4 agents presents a promising avenue in cancer treatment, demonstrating notable
438 efficacy across various cancers, including colorectal cancer (CRC). The concurrent use of
439 nivolumab and ipilimumab, particularly, showcased superior efficacy in terms of objective
440 response rate (ORR), overall survival (OS), and progression-free survival (PFS).
441 Pembrolizumab monotherapy also exhibited promising results, highlighting its efficacy in
442 treating CRC.

443 While the study, encompassing 13 studies with 1337 patients, provides valuable insights into
444 the effectiveness and safety of immunotherapy in CRC, the identified heterogeneity in some
445 outcomes emphasizes the necessity for additional research and exploration. Adverse effects,
446 mainly observed in the gastrointestinal and endocrine systems, were generally low in incidence.
447 Despite the higher incidence of treatment-related grade ≥ 3 adverse events with the nivolumab
448 and ipilimumab combination, the superior efficacy observed supports its consideration as a
449 viable treatment option. This study represents a pioneering systematic review comparing short-
450 term and long-term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC, acknowledging
451 certain limitations and the need for ongoing investigation to refine and validate these findings.

452

453

454 **Data availability**

455 *Underlying data*

456 All data underlying the results are available as part of the article and no additional source
457 data are required.

458 *Reporting guidelines*

459 Mendeley Data doi: 10.17632/zhvz39sggy.1.

460 Data are available under the terms of the Creative Commons Attribution 4.0 International
461 license (CC-BY 4.0).

462

463 **Funding**

464 The author(s) declared no funding information available.

465

466 **Competing interests**

467 No competing interests were disclosed.

468

469 **Grant information**

470 The author(s) declared that no grants were involved in supporting this work.

471

472 **Acknowledgment**

473 We would like to express our sincere gratitude to the Indonesian Health Research Foundation
474 for their invaluable contribution in reviewing and enhancing the quality of this systematic
475 review and meta-analysis. Their expertise and insightful feedback have significantly enriched
476 the rigor and comprehensiveness of our research. We acknowledge the Foundation's
477 commitment to advancing healthcare research and their dedication to fostering excellence in
478 scientific inquiry. This collaboration has been instrumental in shaping the robustness of our
479 study, and we extend our heartfelt appreciation for their support in promoting the advancement
480 of health knowledge.

482 Reference

- 483 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
484 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
485 for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
- 486 2. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The
487 global, regional, and national burden of colorectal cancer and its attributable risk factors
488 in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden
489 of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2019 Dec 1;4(12):913–33.
- 490 3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
491 incidence and mortality worldwide: Sources, methods and major patterns in
492 GLOBOCAN 2012. *Int J Cancer*. 2015 Mar 1;136(5):E359–86.
- 493 4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal
494 cancer statistics, 2017. *CA Cancer J Clin*. 2017 May 6;67(3):177–93.
- 495 5. American Cancer Society. Colorectal Cancer Screening* Prevalence (%) among Adults
496 Age 50 Years and Older by State, 2012. 2014.
- 497 6. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-
498 Asian adapted ESMO consensus guidelines for the management of patients with
499 metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO,
500 MOS, SSO and TOS. *Annals of Oncology*. 2018 Jan 1;29(1):44–70.
- 501 7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade
502 in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*. 2015
503 Jun 25;372(26):2509–20.
- 504 8. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al.
505 Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite
506 instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2
507 study. *Lancet Oncol*. 2017 Sep 1;18(9):1182–91.
- 508 9. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair
509 deficiency predicts response of solid tumors to PD-1 blockade. *Science (1979)*. 2017 Jul
510 28;357(6349):409–13.
- 511 10. Heinemann V, KNBH et al. Somatic DNA mutations, tumor mutational burden (TMB),
512 and MSI status: Association with efficacy in patients (pts) with metastatic colorectal
513 cancer (mCRC) of FIRE-3 (AIO KRK-0306). *J Clin Oncol*. 2018;36:3591a.
- 514 11. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al.
515 Mismatch repair status and BRAF mutation status in metastatic colorectal cancer
516 patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
517 *Clinical Cancer Research*. 2014 Oct 15;20(20):5322–30.
- 518 12. Diaz LA, MADJ et al. Pembrolizumab therapy for microsatellite instability high (MSI-H)
519 colorectal cancer (CRC) and non-CRC. *J Clin Oncol*. 2017;35:3071a.

- 520 13. Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and
521 immunotherapy in colorectal cancer with microsatellite instability?: Part II-the
522 challenge of programmed death ligand-1 testing and its role in microsatellite instability-
523 high colorectal cancer. In: *Archives of Pathology and Laboratory Medicine*. College of
524 American Pathologists; 2018. p. 26–34.
- 525 14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12,
526 *Nature Reviews Cancer*. 2012. p. 252–64.
- 527 15. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
528 and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with
529 advanced colorectal carcinoma. *PLoS One*. 2017 Dec 1;12(12).
- 530 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
531 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Vol.
532 372, *The BMJ*. BMJ Publishing Group; 2021.
- 533 17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated
534 guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for
535 Systematic Reviews of Interventions. Vol. 10, *The Cochrane database of systematic*
536 *reviews*. NLM (Medline); 2019. p. ED000142.
- 537 18. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brucher E, Lenz HJ, et al. Safety of
538 Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-
539 High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. *Oncologist*. 2019 Nov
540 1;24(11):1453–61.
- 541 19. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety
542 and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with
543 advanced colorectal carcinoma. *PLoS One*. 2017 Dec 1;12(12).
- 544 20. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et
545 al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients
546 with recurrent carcinoma of the anal canal. *Ann Oncol*. 2017 May 1;28(5):1036–41.
- 547 21. Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D,
548 et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in
549 patients with microsatellite instability-high/mismatch repair-deficient metastatic
550 colorectal cancer: The GERCOR NIPICOL phase II study. *J Immunother Cancer*. 2020
551 Nov 3;8(2).
- 552 22. Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, et al.
553 Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and
554 Relation with Immune Phenotypic Analysis (the ROCK Trial). *Clinical Cancer*
555 *Research*. 2023 Dec 15;29(24):5079–86.
- 556 23. Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab
557 versus chemotherapy for microsatellite instability-high or mismatch repair-deficient
558 metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-
559 label, phase 3 study. *Lancet Oncol*. 2022 May 1;23(5):659–70.

- 560 24. Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, et al. Pembrolizumab
561 in Asian patients with microsatellite-instability-high/mismatch-repair-deficient
562 colorectal cancer. *Cancer Sci*. 2023 Mar 1;114(3):1026–36.
- 563 25. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for
564 previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-
565 arm, phase 2 study. *Lancet Oncol*. 2017 Apr 1;18(4):446–53.
- 566 26. Lenz HJ, Eric ;, Cutsem V, Limon ML, Yeung K, Wong M, et al. First-Line Nivolumab
567 Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-
568 Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. *J Clin*
569 *Oncol* [Internet]. 2021;40:161–70. Available from: [https://doi](https://doi.org/10.1200/JCO.2017).
- 570 27. Overman MJ, Lonardi S, Yeung K, Wong M, Lenz HJ, Gelsomino F, et al. JOURNAL
571 OF CLINICAL ONCOLOGY Durable Clinical Benefit With Nivolumab Plus
572 Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High
573 Metastatic Colorectal Cancer. *J Clin Oncol* [Internet]. 2018;36:773–9. Available from:
574 <https://doi.org/10.1200/JCO.2017>.
- 575 28. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1
576 pathways.
- 577 29. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for
578 cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62,
579 *International Immunopharmacology*. Elsevier B.V.; 2018. p. 29–39.
- 580 30. Ghiringhelli F, Fumet JD. Is There a Place for Immunotherapy for Metastatic
581 Microsatellite Stable Colorectal Cancer? Vol. 10, *Frontiers in immunology*. NLM
582 (Medline); 2019. p. 1816.
- 583 31. Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al.
584 Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in
585 Combination with Ipilimumab in Small-Cell Lung Cancer. *Cancer Cell*. 2018 May
586 14;33(5):853-861.e4.
- 587 32. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al.
588 Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell
589 Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *Journal of*
590 *Thoracic Oncology*. 2020 Mar 1;15(3):426–35.
- 591 33. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal
592 cancer: Current achievements and future perspective. Vol. 17, *International Journal of*
593 *Biological Sciences*. Ivyspring International Publisher; 2021. p. 3837–49.
- 594 34. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al.
595 Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in
596 patients with advanced solid tumors. *Clinical Cancer Research*. 2015 Oct
597 1;21(19):4286–93.

- 598 35. Shao N, Wan F, Zhu Y, Ye D. Conditional survival in patients with advanced renal cell
599 carcinoma treated with nivolumab. *Medical Science Monitor*. 2019 Aug 30;25:6518–
600 22.
- 601 36. Xu Y, Hezam K, Ali MG, Wang Y, Zhang J. The efficacy and safety of Nivolumab
602 combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. Vol. 43,
603 *Immunopharmacology and Immunotoxicology*. Taylor and Francis Ltd.; 2021. p. 386–
604 94.
- 605 37. Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab
606 plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive
607 advanced non-small cell lung cancer: A systematic review and network meta-analysis.
608 Vol. 12, *Cancers*. MDPI AG; 2020. p. 1–19.
- 609 38. Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, et al. Nivolumab monotherapy or
610 combination therapy with ipilimumab for lung cancer: a systemic review and meta-
611 analysis. Vol. 21, *Cancer Cell International*. BioMed Central Ltd; 2021.
- 612 39. O’Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, et al. Long-term
613 comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line
614 therapies for advanced non-small-cell lung cancer: A systematic literature review and
615 network meta-analysis. *Lung Cancer*. 2023 Mar 1;177:11–20.
- 616 40. Serritella A V., Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab Alone in
617 Advanced Cancers Other Than Melanoma: A Meta-Analysis. *JAMA Oncol*. 2023 Oct
618 19;9(10):1441–6.
- 619 41. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety
620 profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Vol. 13,
621 *Nature Reviews Clinical Oncology*. Nature Publishing Group; 2016. p. 473–86.
- 622 42. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint
623 inhibitors are created equal: Meta-analysis and systematic review of immune-related
624 adverse events in cancer trials. Vol. 119, *Critical Reviews in Oncology/Hematology*.
625 Elsevier Ireland Ltd; 2017. p. 1–12.
- 626 43. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related
627 Adverse Events Associated With Monotherapy and Combination Therapy of
628 Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic
629 Review and Meta-Analysis. Vol. 10, *Frontiers in Oncology*. Frontiers Media S.A.; 2020.

630

631




Figure 1. PRISMA 2020 flow diagram




Figure 2. (A) ROBINS-I Risk of Bias Assessment

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	Diaz et al., 2022	+	+	+	+	+	+
	André, et al., 2020	-	+	+	+	+	-
	Yoshino et al., 2022	+	+	-	+	+	-

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
- Some concerns
+ Low





Figure 2. (B) ROB-2 Risk of Bias Assessment



Random-Effects Model (k = 3)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.337	0.0765	4.39	<.001	0.184	0.491

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.106	0.0113 (SE= 0.0187)	64.4%	2.809	.	2.000	4.847	0.089

Figure 3. (A) Forest plot of ORR nivolumab intervention





Figure 3. (B) Funnel plot of ORR nivolumab intervention



Random-Effects Model (k = 4)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	SE	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.534	0.0602	8.88	<.001	0.416	0.652

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics


Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.106	0.0113 (SE= 0.0118)	79.22%	4.811	.	3.000	12.727	0.005

Figure 4. (A) Forest plot of ORR Nivolumab and Ipilimumab.



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4. (B) Funnel plot of ORR Nivolumab and Ipilimumab



Random-Effects Model (k = 6)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	SE	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.336	0.0747	4.50	<.001	0.189	0.482

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.174	0.0302 (SE= 0.0211)	93.87%	16.320	.	5.000	73.918	<.001

Figure 5. (A) Forest plot of ORR Pembrolizumab intervention





Figure 5. (B) Funnel plot of ORR Pembrolizumab intervention



Random-Effects Model (k = 3)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309665>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.678	0.0807	8.40	<.001	0.520	0.836

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.113	0.0127 (SE= 0.0198)	66.26%	2.964	.	2.000	5.848	0.054

Figure 6. (A) Forest plot of OS Nivolumab intervention





Figure 6. (B) Funnel plot of OS Nivolumab intervention



Random-Effects Model (k = 4)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.844	0.0197	42.8	<.001	0.805	0.882

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.000	0 (SE= 0.0013)	0%	1.000	.	3.000	0.060	0.996

Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumab





Figure 7. (B) Funnel plot of OS nivolumab and Ipilimumab



Random-Effects Model (k = 5)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	SE	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.562	0.0958	5.86	<.001	0.374	0.749

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics


Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.203	0.0414 (SE= 0.0324)	95.68%	23.139	.	4.000	105.974	<.001

Figure 8. (A) Forest plot of OS Pembrolizumab intervention



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 8. (B) Funnel plot of OS Pembrolizumab interventions



Random-Effects Model (k = 3)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.533	0.0541	9.86	<.001	0.427	0.639

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.046	0.0021 (SE= 0.0091)	22.35%	1.288	.	2.000	2.626	0.269

Figure 9. (A) Forest plot of PFS Nivolumab intervention





Figure 9. (B) Funnel plot of PFS Nivolumab intervention



Random-Effects Model (k = 4)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	se	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.718	0.0244	29.4	<.001	0.670	0.766

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics


Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.000	0 (SE= 0.0019)	0%	1.000	.	3.000	0.784	0.853

Figure 10. (A) Forest plot of OS Nivolumab and Ipilimumab



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 10. (B) Funnel plot of OS Nivolumab and Ipilimumab



Random-Effects Model (k = 5)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309885>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	se	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.534	0.0973	5.49	<.001	0.343	0.725

Note. Tau² Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau ²	I ²	H ²	R ²	df	Q	p
0.207	0.043 (SE= 0.0335)	95.77%	23.634	.	4.000	63.889	<.001

Figure 11. (A) Forest plot of PFS Pembrolizumab interven




Figure 11. (B) Funnel plot of PFS Pembrolizumab intervention